Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $14.72 ā a decrease of 2% over the previous day. Catalyst Pharmaceuticals employs 167 staff and has a trailing 12-month revenue of around $398.2 million.
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $11.09 up to $17.765. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 0.88. This would suggest that Catalyst Pharmaceuticals's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $14.72
| 1 week (2024-04-25) | -1.14% |
|---|---|
| 1 month (2024-04-04) | -2.97% |
| 3 months (2024-02-04) | 9.93% |
| 6 months (2023-11-02) | 11.85% |
| 1 year (2023-05-04) | -14.47% |
| 2 years (2022-05-04) | 95.48% |
| 3 years (2021-05-04) | 218.61% |
| 5 years (2019-05-02) | 142.90% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Catalyst Pharmaceuticals P/E ratio, PEG ratio and EBITDA
Catalyst Pharmaceuticals's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Catalyst Pharmaceuticals stocks trade at around 24x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $119.7 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.